chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient presents to the emergency department with a complaint of difficulty breathing.  He is somewhat a poor historian and unable to give full account of how long the shortness of breath has been going on was he vaccinated or not or when he tested positive.  His COVID-19 test is positive today.  He is morbidly obese with a history of diabetes, hypercholesterolemia, hypertension, and sleep apnea.  He was placed on BiPAP settings of 12/6 FiO2 60% and saturation at 100% on those settings.  CXR shows Mild cardiomegaly. Findings suggestive of multifocal pneumonia. A left pleural effusion is also suspected. CT of the Abdomen shows  Groundglass opacities with  7/27/2021 tested positive 8/2/2021: patient discharged. Patient presents to the emergency department with a complaint of difficulty breathing.  He is somewhat a poor historian and unable to give full account of how long the shortness of breath has been going on was he vaccinated or not or when he tested positive.  His COVID-19 test is positive today.  He is morbidly obese with a history of diabetes, hypercholesterolemia, hypertension, and sleep apnea.  He was placed on BiPAP settings of 12/6 FiO2 60% and saturation at 100% on those settings.  CXR shows Mild cardiomegaly. Findings suggestive of multifocal pneumonia. A left pleural effusion is also suspected. CT of the Abdomen shows  Groundglass opacities with nodular consolidation scattered throughout the lungs, as described above, consistent with a multifocal pneumonia. Small bilateral pleural effusions with bibasilar atelectasis.2.  Mild cardiomegaly. Mild fusiform aneurysm of the ascending thoracic aorta measuring 4.2 cm.3.  Minimal stranding with layering free fluid in the left paracolic gutter, which may be related to patient's volume status. While this could represent reactive free fluid related to acute diverticulitis, a moderate length segment of the descending colon in this region was excluded from the field-of-view and not well evaluated for diverticulitis. No pneumoperitoneum.4.  Mild focal residual dilation in the downstream left ureter without upstream hydronephrosis. No obstructive ureteral calculus present. A focal area of stricturing or developing ureteral neoplasm could have this appearance and a nonemergent CT urogram is recommended for further characterization.  CT of the Brain shows  No mass effect, hemorrhage or large hypodensity to suggest territorial ischemia. CT sensitivity for subtle acute ischemia is limited. Consider further evaluation with noncontrast MRI if indicated.2.  Age-related involutional changes of the brain and white matter changes of chronic microvascular ischemia.  There is no leukocytosis his hemoglobin 9.6 with a hematocrit 31.8.  MCV shows 103.6.  Glucose is 144 creatinine is 3.59.  We will admit for further evaluation and treatment.
Information has been received from a physician for the pregnancy registry for GARDASIL, concerning a female (age not reported) who on an unspecified date was vaccinated with a dose of GARDASIL.  The physician reported that the patient did not know she was pregnant, she had a miscarriage.  Follow up phone call information provided by a physician's assistant reported that the patient experienced a spontaneous abortion sometime after the first dose of GARDASIL, and prior to the second dose of GARDASIL.  The physician's assistant was unable to provide the administration date, dose, or lot numbers.  It was reported that the patient's outcome was unknown.  Upon internal review, spontaneous abortion was determined to be an other important medical event.  No product quality complaint was involved.  Additional information has been requested.
between 24 and 48 hours after receiving first vaccine patient broke out into blisters all over body.  Particularly severe on shoulders, arms and inner thighs.  Blisters were not itchy, but broke open and discharged.  Patient put on oral steroids course and antibiotic doxycycline.  Testing revealed that it was in fact an allergic reaction.
After a few minutes, patient stood up to walk around, and became light headed and fell down. Became pale and sluggish
Patient reported to RN at 11:46am of numbness to tip of her tongue and fingertips and itching to injection site.  At 11:48am, Clinic Coordinator, RN and IPC Supervisor RN, were notified. At 11:48am, pulse oximeter placed and O2 sat 97% on room air. At 11:50am, BP 126/90, O2 sat 97%, HR 75. Dr. was notified by RN at 11:51am, instructed to initiate emergency protocol.  At 11:57am, epinephrine 0.3ml IM administered. At 12:00pm, Benadryl 50mg IM administered. BP  132/74, O2 sat 99% on room air, HR 112. At 12:02pm, O2 @ 2L/NC started by RN. At 12:05pm, O2 sat 99%, HR 98. At 12:08pm, epinephine 0.3ml IM administered. At 12:10pm, EMS arrived. Vitals/assessment by EMS: BP 143/88, HR 94, O2 sat 99% on 2L O2, lungs clear, EKG in normal sinus rhythm.  Patient declined EMS transport to the ER. At 12:40pm, patient reported itching to injection site had resolved. At approximately 12:55pm, patient was picked up by spouse in stable condition.
Patient passed out after receiving vaccination. He was unconscious for about 5 seconds before regaining consciousness.
This spontaneous report as received from a physician refers to a 70 year old male patient with hypertension, hyperlipidemia, sleep apnea, gout, Benign prostatic hyperplasia (BPH), restless leg syndrome and degenerative joint disease. The patient's medical history included bypass surgery in 2005. The patient had no drug reactions/allergies. On 26-SEP-2013 the patient was vaccinated with ZOSTAVAX (dose, route and lot number were not reported). Concomitant therapies included FLONASE, metoprolol, lisinopril (manufacturer unknown), simvastatin (manufacturer unknown), nitroglycerin, indomethacin, baclofen, allopurinol and baby aspirin. Physician reported that the patient developed a rash on 28-SEP-2013. Physician reported that patient was seen the day of the report, on 02-OCT-2013, in the office. Physician reported that patient had a dermatome distribution of severe shingles in the lower thoracic region - front to back. Physician reported that this was the worst case of shingles he had ever seen, the patient had over 1,000 vesicles. Physician reported that he treated with VALTREX and drew unspecified blood labs, all of which were normal. The outcome of shingles was reported as not recovered/not resolved. The relationship between ZOSTAVAX and the events was not reported. Additional information has been requested.
onset 10 1/2 hrs approx woke cryig, given APAP & bottle of H20, irritable & unable to sleep, rash noted 8AM 30DEC, lt side of body, fever 102 @ MD office 10AM;
pt devel fine red rash on back (over scapula) on Sep 1; no fever, did not see MD; rash still barely visible;
Patient reported feeling dizzy while waiting in the car, approximately 5 minutes after receiving the vaccine, stating her vision began to blur. VS BP 100/60, HR 51, O2 sat 93% on room air. Patient appeared lethargic, unable to keep eyes open when instructed by personnel, upper and lower extremities were limp, unable to keep upper extremities up with full strength or cooperation. Encouraged by personnel to practice deep breathing exercises, compliant until she began feeling tired. Able to understand commands provided by personnel. EMS and police department arrived to scene within 5 minutes. Upon assessment from parademic, patient vitals WNL. Encouraged to go to the hospital by paramedic, patient did not want to go despite feeling dizzy. Aquaintance/close relative on the scene, was responsible of taking patient's car. Relative encouraged patient to go to the hospital, patient refused saying she was feeling better. Patient was able to transfer self from driver's seat to the passenger seat, steady gait. Relative was waiting with patient in patient's car, relative behind the wheel, at the parking lot to monitor patient. Wait approximately 20 minutes before heading home. RN provided education on signs and symptoms to monitor once arriving home, and to seek medical help if conditions worsen.
This spontaneous report was received from an administrator, concerning an unspecified number of patients of an unknown age and gender. The patients' medical history, concurrent conditions, concomitant medications, drug reactions or allergies were not reported. On an unspecified date, the patients were vaccinated with an improperly stored VARIVAX with lot # L029472 and L050956, expiration dates on 06-AUG-2017 and 17-DEC-2017, respectively (strength, dose, frequency, route of administration and anatomical location were not provided), for prophylaxis. The storage temperature and the time frame were unspecified by the reporter, but it was reported that there was a previous temperature excursion. No adverse symptoms were reported. No product quality complaint (PQC) was involved. Additional information has been requested.
A nurse reported that a patient received an injection of Flu Shield (2001-2002 Formula) and subsequently developed an injection site reaction characterized by a quarter to half dollar-sized area of redness and heat. The patient was treated with Tylenol (acetaminophen) and applications of ice to the affected area. NO further information was available at the date of this report. Manufacturer's Comment: The reporter indicated that 24 patients experienced this event; however, they are not presently identifiable. Additional reports will be generated when identifying information is provided.
Bump and rash at injection site developed 24 hr after injection. Treated with ice bag and TYLENOL. Subsided after another 24 hrs.
Admitted for COVID pna. Fully vaccinated. Treated with O2, abx, remdesivir, steroids, zinc. Improved and discharged home.
Client presented to the vaccination site on 12/02/2021 accompanied by her parent for her first dose Pfizer COVID vaccine. Today, the client received the first dose Pfizer COVID vaccine for 5 through 11 years of age (Lot #: FK5127 exp: 01/24/22) at 1602. RN noted the client was 14 years old after administration of the first dose Pfizer COVID vaccine for 5 through 11 years of age. PHN provided education to client?s parent stating the client received the incorrect formulation of the Pfizer COVID vaccine after RN notified PHN. PHN educated client?s parent and client on possible adverse reactions and when to seek medical care. The client denied any chronic conditions, current medications, or known allergies. PHN submitted a medical consult via text message to Clinical Project Coordinator, requesting for guidance on how to proceed. PHN received recommendation from the doctor was received via text message from Clinical Project Coordinator. The doctor recommended against repeat vaccination today but stated in 21 days the client may receive a second dose of Pfizer COVID vaccine for 12 years of age and older at the parent's request. PHN talked to the client's parent at the EMT station. PHN provided education regarding administration of the incorrect formulation of the Pfizer COVID vaccine and the recommendation from the doctor stating the client may receive a second dose Pfizer COVID vaccine for 12 years of age and older in 21 days, and that client?s appointment is scheduled for 12/27/21. PHN provided education to the client's parent again regarding possible adverse reactions, and when to seek medical care. The client did not report any symptoms during the 30-minute observation period. The client left the vaccination site with her parent at 1632 ambulating unassisted with a steady gait.
Severe headache, sinus congestion, dizziness, nausea, diarrhea, heavy menstrual period, fatigue, drowsy, muscle pain, injection site soreness
pt began choking, gagging & spitting up some yellowish phlegm;pt very lethargic & sleepy;would not wake up & would not respond appropriately to mom;cont to have intermittent gagging choking spells;some lip smacking;dx gastroenteritis;
24 hrs p/receiving Td, pt devel swollen & grayish oribital areas, fever, h/a, generalized muscular & joint pains, & lymphadenopathy; Pred given to treat rxn; exp dysphagia
This spontaneous case was reported by a consumer and describes the occurrence of PAIN (pain disorder got worst), BURNING FEET SYNDROME (feet burns/ my feet felt like they were on fire) and BURNING SENSATION (nerves of arms burn/ burning in my feet and up to my knees) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M2DA) for COVID-19 vaccination. The patient's past medical history included Pitting edema (Patient stated that she has had problems of pedal and ankle pitting edema.). Concurrent medical conditions included Arachnoiditis adhesive chronic. Concomitant products included MORPHINE, AMLODIPINE, FUROSEMIDE, METILPREDNISOLONE, ATORVASTATIN, LEVOTHYROXINE, CALCIUM CITRATE, CALCIUM CITRATE MALATE, MAGNESIUM (OSSOPAN MCM), VITAMIN B COMPLEX, VITAMIN D3, DOCUSATE SODIUM, CURCUMA LONGA (TURMERIC CURCUMIN [CURCUMA LONGA]), FISH OIL and PREGNENOLONE for an unknown indication. On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, the patient experienced PAIN (pain disorder got worst), BURNING FEET SYNDROME (feet burns/ my feet felt like they were on fire) and BURNING SENSATION (nerves of arms burn/ burning in my feet and up to my knees). At the time of the report, PAIN (pain disorder got worst), BURNING FEET SYNDROME (feet burns/ my feet felt like they were on fire) and BURNING SENSATION (nerves of arms burn/ burning in my feet and up to my knees) outcome was unknown.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Alanine aminotransferase increased: high (High) Patient stated that her test results showed slight elevation of ALT. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. Treatment included strong pain medicine. Patient was scheduled to get the second dose of vaccine on 26-Mar-2021. Patient was on diabetic controlled diet and had neuropathy problems in relation with her arachnoiditis. patient was also stated that the event burning sensation in  feet to below knees has been continuing since receiving the first dose of vaccine. Most recent FOLLOW-UP information incorporated above includes: On 31-May-2021: follow-up received and Updated lab data. Added medical history (pitting edema).
Onset began less than 24 hours after the vaccination, Triggered what could only be described bursitis a sharp pain in my shoulder and its still there as we speak. near where I received my vaccination. The doctor did not think the vaccine could cause bursitis. but it happened right after I received the vaccine. The nutrients that I am taking are inflammatory, so the doctor did not give me anything . I'm just taking the nutrients because they don't have  treatment for bursitis. My guess is the vaccine triggered something that was going to happen anyway. Oddly enough I only have the bursitis only in that shoulder. Found on the internet: sirva- is caused by a vaccine is administered too high or too deep going through the muscle or going through bursa.
Missed second dose; This spontaneous case was reported by a patient and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed second dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Not Provided) for COVID-19 vaccination.     No Medical History information was reported.    On 27-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed second dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed second dose) had resolved.            No concomitant medications were reported.  No treatment  medications were reported.
can hardly lift her arm; red rash, tenderness and itchiness at the injection site; red rash, tenderness and itchiness at the injection site; red rash, tenderness and itchiness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (can hardly lift her arm), VACCINATION SITE PAIN (red rash, tenderness and itchiness at the injection site), VACCINATION SITE RASH (red rash, tenderness and itchiness at the injection site) and VACCINATION SITE PRURITUS (red rash, tenderness and itchiness at the injection site) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, the patient experienced VACCINATION SITE PAIN (red rash, tenderness and itchiness at the injection site), VACCINATION SITE RASH (red rash, tenderness and itchiness at the injection site) and VACCINATION SITE PRURITUS (red rash, tenderness and itchiness at the injection site). On 17-Feb-2021, the patient experienced MUSCULAR WEAKNESS (can hardly lift her arm). At the time of the report, MUSCULAR WEAKNESS (can hardly lift her arm), VACCINATION SITE PAIN (red rash, tenderness and itchiness at the injection site), VACCINATION SITE RASH (red rash, tenderness and itchiness at the injection site) and VACCINATION SITE PRURITUS (red rash, tenderness and itchiness at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication details were not reported by the reporter. Treatment details was not reported by the reporter.
I had severe abdominal pain for two days in which I could not sleep, or sit down without pain. I went to the emergency room, and they treated me for stomach ulcers. I had never had this kind of pain or any other similar health problems in the past.
Client reports that she felt light-headed,  nauseous and hot.  She also reported that she felt sick and had cramping to both hands, approximately 1-2 minutes after receiving dose one of the Pfizer vaccine.  Her symptoms lasted 5-10 minutes.  After approximately 15-20 of observation, client reports she was feeling better, and left the premises on her own.
Began in the evenings when I went to bed. Worsened over time becoming all-day problem. Erratic Heartbeat, elevated blood pressure, palpitations, hypertension, chest pain, shortness of breath. Treated in Urgent Care, 6/16. CTA Aorta for Dissection ordered, 6/18. Transthoracic Echo ordered, 7/27. No diagnosis. No treatment. Symptoms subsided through July and August. Feel normal/healthy now.
8/28/15 Mom called office to state right arm was red, swollen, hard oval area the size of mom's palm of her hand. 1st noticed 7pm 8/27/15 took BENADRYL and TYLENOL with mild relief.
Patient awoke 11/1/06 with reddened area 3 1/4" & 2 1/2" on L arm, laterally. Reports tenderness in area. Area of inflammation is 3-4" distal to deltoid. Denies fever. States was tired and had rhinitis but not other symptoms. Took Tylenol 10/30/06. No axillary node involvement.
Dry cough started around 3 pm, cough similar to that of mild asthma. About 7 pm, about 3 itchy bumps on chin appeared. At 10 pm, small hives appeared on neck, chin, cheeks, forehead, chest, and back. The 24/7 registered nurse service was called. Symptoms were described to nurse as well as answering additional questions on severity or signs of other symptoms. Nurse identified symptoms as an allergic reaction to the vaccine and advised to take benadryl and seek immediate medical attention with worsening symptoms. 2 benadryl tablets were taken (as prescribed on the bottle for adults). Symptoms were clearly lessened after two hours, including breathing noticeably returning to normal and no cough. No sign of hives or other symptoms by morning.
My mouth was little numbness -upper level and tongue; dizziness; hot; My face was red and itchy; My face was red and itchy; This is a spontaneous report from a contactable consumer, the patient. A 50-years-old non pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 m-RNA VACCINE, formulation: solution for injection, lot number was not reported), via an unspecified route of administration, in arm left on 18Oct2021 at 15:15 as dose 1, single (age at vaccination 50 years) for covid-19 immunisation. Medical history included allergy to penicillin since an unknown date. The patient was allergic to pneumonia 23 vaccine. The patient's concomitant medications were not reported. The patient after 5 minutes of vaccination got dizziness and hot, her face was red and itchy and her mouth had little numbness -upper level and tongue an 18Oct2021 at 15:30. Therapeutic measures were taken as a result of the events that included taking twice loratadine at same day. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not tested for covid post vaccination. The outcome of the events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Fever, fatigue, headache All symptoms began about 9-10 hours after receiving the vaccine. Treated with acetaminophen. Symptoms lasted throughout the day after receiving the vaccine and subsided by 2 days after receiving the vaccine.
Husband called office - pt had numbness in lips. (-) sob. Husband had received same injection, same 6+ # with no se. Advised stat ER visit. Came to Aferian Bros ER same day. Tx with po steriods/benadryl and released. Fine 3/11/06 called office.
Approx. 5-10 minutes after receiving Boostrix and Menactra shots child c/o sore throat and trouble breathing.  Pt pale and mild wheezing.  Xopenex treatment started 2:40pm. Pulse Ox at 2:43pm 89-91% RR20 BP 70/32. Pulse ox at end of treatment 99%. Patient felt he was breathing easier.  BP #2 after 1st treatment was 88154.  Color returned, some wheezing still noted.  Xopenex treatment #2 started at 3:05pm per MD orders.  Pulse ox at that time was 95% doctor reassessed pt after that treatment and released patient with mom.
SIDE EFFECTS; This spontaneous report received from a patient concerned a 77 year old male. The patient's height, and weight were not reported. The patient's past medical history included eye surgeries.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number was not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included abiraterone acetate for drug used for unknown indication. On an unspecified date, the subject experienced side effects. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of side effects was not reported. This report was non-serious.
pt mom reported redness & swelling of lt arm @ inject site; 3 1/2 inches in length hot to touch; no fever; advised to monitor swelling if increases or elevated temp to call office; advised APAP & ice;
The patient had a shot on 02/18/1999, then on 02/19/1999 she still had pain in her left knee with a lot of swelling. The patient reported to the doctor 03/01/1999, was treated with Relafen. The patient then went to the orthopedist 03/10/1999 and got a second shot, on 03/18/1999 she reacted again.  The patient went back to the doctor on 04/15/1999, and the rheumatologist on 05/07/1999, she was treated with Relafen and Ultram. The patient has pain and intermittent swelling to this day.